| Alimemazine | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | |
| Alimemazine | hsa00040 | Pentose and glucuronate interconversions | 4.00E-02 | 1 | P15121 | AKR1B1 | More | |
| Alimemazine | hsa00052 | Galactose metabolism | 1.03E-02 | 2 | P06280, O43451 | GLA, MGAM | More | |
| Alimemazine | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | |
| Alimemazine | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | |
| Alimemazine | hsa00240 | Pyrimidine metabolism | 4.29E-02 | 2 | P21589, P04183 | NT5E, TK1 | More | |
| Alimemazine | hsa00500 | Starch and sucrose metabolism | 1.67E-02 | 2 | O43451, P06737 | MGAM, PYGL | More | |
| Alimemazine | hsa00513 | Various types of N-glycan biosynthesis | 4.96E-02 | 1 | Q9NR34 | MAN1C1 | More | |
| Alimemazine | hsa00564 | Glycerophospholipid metabolism | 4.29E-02 | 2 | Q6P1A2, P23743 | MBOAT5, DGKA | More | |
| Alimemazine | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | |
| Alimemazine | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | |
| Alimemazine | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | |
| Alimemazine | hsa00600 | Sphingolipid metabolism | 3.76E-02 | 1 | P15289 | ARSA | More | |
| Alimemazine | hsa00620 | Pyruvate metabolism | 3.90E-02 | 2 | P07195, P11766 | LDHB, ADH5 | More | |
| Alimemazine | hsa00730 | Thiamine metabolism | 5.29E-03 | 2 | P05186, P24666 | ALPL, ACP1 | More | |
| Alimemazine | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | |
| Alimemazine | hsa00790 | Folate biosynthesis | 2.02E-02 | 1 | P15121 | AKR1B1 | More | |
| Alimemazine | hsa00970 | Aminoacyl-tRNA biosynthesis | 2.12E-02 | 1 | P14868 | DARS | More | |
| Alimemazine | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 6.38E-04 | 3 | P78417, P09211, P11712 | GSTO1, GSTP1, CYP2C9 | More | |
| Alimemazine | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | |
| Alimemazine | hsa00983 | Drug metabolism - other enzymes | 2.44E-02 | 2 | P32320, P05164 | CDA, MPO | More | |
| Alimemazine | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | |
| Alimemazine | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | |
| Alimemazine | hsa02010 | ABC transporters | 2.17E-03 | 3 | P45844, P08183, Q8IZY2 | ABCG1, ABCB1, ABCA7 | More | |
| Alimemazine | hsa03010 | Ribosome | 1.08E-04 | 11 | P62753, P25398, P32969, P40429, P62829, Q07020, P18077, P36578, P27635, P05386, P62249 | RPS6, RPS12, RPL9, RPL13A, RPL23, RPL18, RPL35A, RPL4, RPL10, RPLP1, RPS16 | More | |
| Alimemazine | hsa03013 | RNA transport | 3.98E-02 | 9 | P52298, O14893, P61326, Q7Z3B4, P35658, Q14152, O75822, P78345, Q9Y6A5 | NCBP2, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF3J, RPP38, TACC3 | More | |
| Alimemazine | hsa03020 | RNA polymerase | 3.59E-02 | 2 | P30876, P62487 | POLR2B, POLR2G | More | |
| Alimemazine | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | |
| Alimemazine | hsa03050 | Proteasome | 4.83E-02 | 1 | P55036 | PSMD4 | More | |
| Alimemazine | hsa03060 | Protein export | 4.46E-03 | 2 | Q15070, O76094 | OXA1L, SRP72 | More | |
| Alimemazine | hsa03430 | Mismatch repair | 4.38E-02 | 1 | P20585 | MSH3 | More | |
| Alimemazine | hsa03450 | Non-homologous end-joining | 4.21E-02 | 1 | P13010 | XRCC5 | More | |
| Alimemazine | hsa04015 | Rap1 signaling pathway | 2.13E-03 | 6 | P06213, P25116, Q8TEU7, O00522, P08514, P17252 | INSR, F2R, RAPGEF6, KRIT1, ITGA2B, PRKCA | More | |
| Alimemazine | hsa04071 | Sphingolipid signaling pathway | 6.19E-05 | 8 | P21453, Q9H228, P01375, Q13362, Q9BX95, Q16539, P10415, Q9UQC2 | S1PR1, EDG8, TNF, PPP2R5C, SGPP1, MAPK14, BCL2, GAB2 | More | |
| Alimemazine | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | |
| Alimemazine | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | |
| Alimemazine | hsa04141 | Protein processing in endoplasmic reticulum | 4.88E-02 | 4 | P18848, O60337, P11142, P07900 | ATF4, MARH6, HSPA8, HSP90AA1 | More | |
| Alimemazine | hsa04146 | Peroxisome | 2.42E-02 | 5 | O43933, P56589, Q9UKG9, O75521, P33121 | PEX1, PEX3, CROT, ECI2, ACSL1 | More | |
| Alimemazine | hsa04210 | Apoptosis | 3.58E-02 | 4 | O76075, P01375, Q9NR28, Q16548 | DFFB, TNF, DIABLO, BCL2A1 | More | |
| Alimemazine | hsa04213 | Longevity regulating pathway - multiple species | 2.85E-02 | 2 | Q9Y4H2, Q13547 | IRS2, HDAC1 | More | |
| Alimemazine | hsa04217 | Necroptosis | 4.24E-05 | 10 | P01375, P48023, Q14765, P07900, P15104, P05141, P01584, P0C0S5, Q99878, Q13557 | TNF, FASLG, STAT4, HSP90AA1, GLUL, SLC25A5, IL1B, H2AFZ, H2AC14, CAMK2D | More | |
| Alimemazine | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | |
| Alimemazine | hsa04340 | Hedgehog signaling pathway | 3.32E-02 | 2 | P49841, P22694 | GSK3B, PRKACB | More | |
| Alimemazine | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | |
| Alimemazine | hsa04610 | Complement and coagulation cascades | 2.33E-03 | 1 | P0C0L4 | C4A | More | |
| Alimemazine | hsa04611 | Platelet activation | 3.39E-02 | 3 | P25116, P08514, P07359 | F2R, ITGA2B, GP1BA | More | |
| Alimemazine | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | |
| Alimemazine | hsa04613 | Neutrophil extracellular trap formation | 2.22E-06 | 22 | P11215, O60603, P05164, P08246, Q9UM07, Q13547, P04908, Q6FI13, Q93077, P58876, P62807, Q16778, O60814, P68431, Q15080, P20160, P08311, O75015, P21730, P21462, O43315, Q16539 | ITGAM, TLR2, MPO, ELA2, PADI4, HDAC1, H2AC4; H2AC8, H2AC18; H2AC19, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF4, AZU1, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | |
| Alimemazine | hsa04650 | Natural killer cell mediated cytotoxicity | 5.05E-04 | 7 | P01375, P20963, Q13241, P26718, P26717, Q14953, P26715 | TNF, CD247, KLRD1, KLRK1, KLRC2, KIR2DS5, KLRC1 | More | |
| Alimemazine | hsa04657 | IL-17 signaling pathway | 5.66E-05 | 10 | P07900, O00463, Q16539, P49841, P19875, P14780, Q9UJX4, P80188, P01375, P01584 | HSP90AA1, TRAF5, MAPK14, GSK3B, CXCL2, MMP9, ANAPC5, LCN2, TNF, IL1B | More | |
| Alimemazine | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | |
| Alimemazine | hsa04672 | Intestinal immune network for IgA production | 1.35E-02 | 2 | P29965, P13765 | CD40LG, HLA-DOB | More | |
| Alimemazine | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | |
| Alimemazine | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | |
| Alimemazine | hsa04910 | Insulin signaling pathway | 2.35E-02 | 3 | P22694, P06737, P49841 | PRKACB, PYGL, GSK3B | More | |
| Alimemazine | hsa04913 | Ovarian steroidogenesis | 2.45E-03 | 3 | P42330, P22694, P06213 | AKR1C3, PRKACB, INSR | More | |
| Alimemazine | hsa04918 | Thyroid hormone synthesis | 3.16E-02 | 2 | P17252, P27824 | PRKCA, CANX | More | |
| Alimemazine | hsa04919 | Thyroid hormone signaling pathway | 7.11E-03 | 4 | P49841, P22694, O60244, Q9NVC6 | GSK3B, PRKACB, MED14, MED17 | More | |
| Alimemazine | hsa04923 | Regulation of lipolysis in adipocytes | 3.76E-02 | 1 | P06213 | INSR | More | |
| Alimemazine | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | |
| Alimemazine | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | |
| Alimemazine | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | |
| Alimemazine | hsa04930 | Type II diabetes mellitus | 3.14E-02 | 1 | P06213 | INSR | More | |
| Alimemazine | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | |
| Alimemazine | hsa04932 | Non-alcoholic fatty liver disease | 6.73E-05 | 9 | P01375, P49841, P18848, P48023, P01584, P13073, O15239, Q16718, O14521 | TNF, GSK3B, ATF4, FASLG, IL1B, COX4I1, NDUFA1, NDUFA5, SDHD | More | |
| Alimemazine | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Alimemazine | hsa04960 | Aldosterone-regulated sodium reabsorption | 3.14E-02 | 1 | P06213 | INSR | More | |
| Alimemazine | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | |
| Alimemazine | hsa04966 | Collecting duct acid secretion | 4.93E-02 | 1 | P00918 | CA2 | More | |
| Alimemazine | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | |
| Alimemazine | hsa04976 | Bile secretion | 1.67E-03 | 3 | O43315, P22694, P08183 | AQP9, PRKACB, ABCB1 | More | |
| Alimemazine | hsa05012 | Parkinson disease | 2.53E-02 | 5 | O15239, P13073, P05141, P18848, Q13557 | NDUFA1, COX4I1, SLC25A5, ATF4, CAMK2D | More | |
| Alimemazine | hsa05016 | Huntington disease | 3.21E-02 | 5 | O15239, P13073, P30876, P62487, P05141 | NDUFA1, COX4I1, POLR2B, POLR2G, SLC25A5 | More | |
| Alimemazine | hsa05020 | Prion disease | 3.73E-04 | 11 | P13591, P01584, P11142, O15239, Q16718, O14521, P13073, P18848, P05141, P49841, Q16539 | NCAM1, IL1B, HSPA8, NDUFA1, NDUFA5, SDHD, COX4I1, ATF4, SLC25A5, GSK3B, MAPK14 | More | |
| Alimemazine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.47E-03 | 12 | P49841, O15239, Q16718, O14521, P13073, P18848, Q13561, P05141, Q16539, P01584, Q08752, Q13557 | GSK3B, NDUFA1, NDUFA5, SDHD, COX4I1, ATF4, DCTN2, SLC25A5, MAPK14, IL1B, PPID, CAMK2D | More | |
| Alimemazine | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | |
| Alimemazine | hsa05034 | Alcoholism | 2.05E-05 | 7 | Q13547, Q93077, P58876, P62807, Q16778, O60814, P68431 | HDAC1, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
| Alimemazine | hsa05133 | Pertussis | 4.20E-02 | 1 | P0C0L4 | C4A | More | |
| Alimemazine | hsa05134 | Legionellosis | 1.28E-02 | 3 | P01584, P68104, P11142 | IL1B, EEF1A1, HSPA8 | More | |
| Alimemazine | hsa05143 | African trypanosomiasis | 7.50E-04 | 4 | P01375, P69905, P68871, P48023 | TNF, HBA2, HBB, FASLG | More | |
| Alimemazine | hsa05144 | Malaria | 1.44E-03 | 5 | P69905, P68871, P01375, P35443, P26718 | HBA2, HBB, TNF, THBS4, KLRK1 | More | |
| Alimemazine | hsa05146 | Amoebiasis | 2.41E-02 | 4 | P19875, P01375, P30679, P22694 | CXCL2, TNF, GNA15, PRKACB | More | |
| Alimemazine | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | |
| Alimemazine | hsa05162 | Measles | 4.02E-02 | 3 | P11142, P01584, Q9NP90 | HSPA8, IL1B, RAB9B | More | |
| Alimemazine | hsa05171 | Coronavirus disease - COVID-19 | 6.98E-05 | 12 | P01584, P62753, P25398, P62249, P40429, P36578, P32969, P27635, Q07020, P18077, P05386, P62829 | IL1B, RPS6, RPS12, RPS16, RPL13A, RPL4, RPL9, RPL10, RPL18, RPL35A, RPLP1, RPL23 | More | |
| Alimemazine | hsa05202 | Transcriptional misregulation in cancer | 1.62E-03 | 15 | Q15532, P41732, P14780, P27930, P14923, Q16548, P11215, Q13077, O15550, P35226, P05164, P08246, Q13547, P12980, P24522 | SS18, TSPAN7, MMP9, IL1R2, JUP, BCL2A1, ITGAM, TRAF1, UTX, BMI1, MPO, ELA2, HDAC1, LYL1, GADD45A | More | |
| Alimemazine | hsa05203 | Viral carcinogenesis | 1.22E-03 | 6 | Q13547, Q15283, P58876, P62807, Q16778, O60814 | HDAC1, RASA2, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12 | More | |
| Alimemazine | hsa05204 | Chemical carcinogenesis | 1.09E-03 | 3 | P09211, P78417, P11712 | GSTP1, GSTO1, CYP2C9 | More | |
| Alimemazine | hsa05205 | Proteoglycans in cancer | 4.46E-03 | 9 | Q12955, Q14247, P14780, P17252, P01375, P23588, Q13635, P22694, P08962 | ANK3, CTTN, MMP9, PRKCA, TNF, EIF4B, PTCH1, PRKACB, CD63 | More | |
| Alimemazine | hsa05310 | Asthma | 1.35E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | |
| Alimemazine | hsa05320 | Autoimmune thyroid disease | 3.16E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | |
| Alimemazine | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | |
| Alimemazine | hsa05322 | Systemic lupus erythematosus | 4.80E-06 | 7 | P09871, Q93077, P58876, P62807, Q16778, O60814, P68431 | C1S, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
| Alimemazine | hsa05330 | Allograft rejection | 1.76E-03 | 4 | P13765, P29965, P48023, P01375 | HLA-DOB, CD40LG, FASLG, TNF | More | |
| Alimemazine | hsa05332 | Graft-versus-host disease | 7.27E-04 | 4 | P48023, P01375, P26715, Q13241 | FASLG, TNF, KLRC1, KLRD1 | More | |
| Alimemazine | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 2.77E-03 | 4 | P54284, P14923, P08514, Q9UJU2 | CACNB3, JUP, ITGA2B, LEF1 | More | |
| Alimemazine | hsa05415 | Diabetic cardiomyopathy | 1.02E-03 | 8 | P05141, O15239, Q16718, O14521, P13073, Q16539, P49841, Q13557 | SLC25A5, NDUFA1, NDUFA5, SDHD, COX4I1, MAPK14, GSK3B, CAMK2D | More | |
| Alimemazine | hsa05416 | Viral myocarditis | 4.29E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | |
